You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCryptenamine
Accession NumberDB00785  (APRD00890)
TypeSmall Molecule
GroupsApproved
DescriptionCryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
UnitensenMEDA AB
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQVO4N8484O
CAS number1356-18-9
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationFor the treatment of hypertension.
Structured Indications Not Available
PharmacodynamicsCryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.
Mechanism of actionCryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known. Some evidence has suggested that cryptenamine acts in a similar fashion to atropine, which lowers the "rest and digest" activity of all muscles and glands regulated by the parasympathetic nervous system. This occurs because atropine is a competitive inhibitor of the muscarinic acetylcholine receptors (acetylcholine is the neurotransmitter used by the parasympathetic nervous system). Therefore muscarinic acetylcholine receptors will be listed as experimental targets for cryptenamine.
TargetKindPharmacological actionActionsOrganismUniProt ID
Muscarinic acetylcholine receptor M2Proteinyes
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M1Proteinyes
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M3Proteinyes
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinyes
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinyes
antagonist
HumanP08912 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Cryptenamine.Experimental
AcebutololCryptenamine may increase the hypotensive activities of Acebutolol.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Cryptenamine.Approved, Investigational
AliskirenCryptenamine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololCryptenamine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanCryptenamine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineCryptenamine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Cryptenamine.Approved
AtenololAtenolol may increase the hypotensive activities of Cryptenamine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Cryptenamine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Cryptenamine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Cryptenamine.Withdrawn
BepridilCryptenamine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Cryptenamine.Approved
BethanidineBethanidine may increase the hypotensive activities of Cryptenamine.Approved
BimatoprostCryptenamine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Cryptenamine.Approved
BosentanBosentan may increase the hypotensive activities of Cryptenamine.Approved, Investigational
BretyliumCryptenamine may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Cryptenamine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Cryptenamine.Approved
BupranololCryptenamine may increase the hypotensive activities of Bupranolol.Approved
CandesartanCryptenamine may increase the hypotensive activities of Candesartan.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Cryptenamine.Experimental
CaptoprilCryptenamine may increase the hypotensive activities of Captopril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Cryptenamine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Cryptenamine.Approved
CarvedilolCryptenamine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololCryptenamine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideCryptenamine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Cryptenamine.Approved
CilazaprilCryptenamine may increase the hypotensive activities of Cilazapril.Approved
ClonidineClonidine may increase the hypotensive activities of Cryptenamine.Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Cryptenamine.Approved
DebrisoquinCryptenamine may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineCryptenamine may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Cryptenamine.Approved
DihydralazineCryptenamine may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Cryptenamine.Approved
DorzolamideCryptenamine may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Cryptenamine.Approved
EfonidipineCryptenamine may increase the hypotensive activities of Efonidipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Cryptenamine.Approved, Vet Approved
EnalaprilatCryptenamine may increase the hypotensive activities of Enalaprilat.Approved
EpoprostenolCryptenamine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanCryptenamine may increase the hypotensive activities of Eprosartan.Approved
FelodipineCryptenamine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenoldopamCryptenamine may increase the hypotensive activities of Fenoldopam.Approved
FosinoprilFosinopril may increase the hypotensive activities of Cryptenamine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Cryptenamine.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Cryptenamine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Cryptenamine.Approved
GuanethidineCryptenamine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineCryptenamine may increase the hypotensive activities of Guanfacine.Approved, Investigational
HexamethoniumCryptenamine may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineHydracarbazine may increase the hypotensive activities of Cryptenamine.Approved
HydralazineCryptenamine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideCryptenamine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Cryptenamine.Approved
IloprostIloprost may increase the hypotensive activities of Cryptenamine.Approved, Investigational
ImidaprilCryptenamine may increase the hypotensive activities of Imidapril.Investigational
IndapamideCryptenamine may increase the hypotensive activities of Indapamide.Approved
IndenololCryptenamine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminCryptenamine may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Cryptenamine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Cryptenamine.Withdrawn
IrbesartanCryptenamine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Cryptenamine.Approved
IsradipineIsradipine may increase the hypotensive activities of Cryptenamine.Approved
KetanserinCryptenamine may increase the hypotensive activities of Ketanserin.Investigational
LabetalolLabetalol may increase the hypotensive activities of Cryptenamine.Approved
LacidipineCryptenamine may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Cryptenamine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Cryptenamine.Approved, Investigational
LofexidineCryptenamine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Cryptenamine.Approved
MacitentanCryptenamine may increase the hypotensive activities of Macitentan.Approved
ManidipineCryptenamine may increase the hypotensive activities of Manidipine.Approved
MebanazineMebanazine may increase the hypotensive activities of Cryptenamine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Cryptenamine.Approved
MethyldopaCryptenamine may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Cryptenamine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Cryptenamine.Approved, Investigational
MetipranololCryptenamine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Cryptenamine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Cryptenamine.Approved, Investigational
MetyrosineCryptenamine may increase the hypotensive activities of Metyrosine.Approved
MibefradilCryptenamine may increase the hypotensive activities of Mibefradil.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Cryptenamine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Cryptenamine.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Cryptenamine.Approved
MoexiprilMoexipril may increase the hypotensive activities of Cryptenamine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Cryptenamine.Approved
MoxonidineCryptenamine may increase the hypotensive activities of Moxonidine.Approved
NadololCryptenamine may increase the hypotensive activities of Nadolol.Approved
NaftopidilCryptenamine may increase the hypotensive activities of Naftopidil.Investigational
NebivololCryptenamine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Cryptenamine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Cryptenamine.Approved
NicorandilCryptenamine may increase the hypotensive activities of Nicorandil.Approved
NiguldipineCryptenamine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineCryptenamine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineNimodipine may increase the hypotensive activities of Cryptenamine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Cryptenamine.Approved
NitrendipineCryptenamine may increase the hypotensive activities of Nitrendipine.Approved
NitroprussideNitroprusside may increase the hypotensive activities of Cryptenamine.Approved
ObinutuzumabCryptenamine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Cryptenamine.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Cryptenamine.Approved, Investigational
OmapatrilatCryptenamine may increase the hypotensive activities of Omapatrilat.Investigational
OxprenololCryptenamine may increase the hypotensive activities of Oxprenolol.Approved
PargylinePargyline may increase the hypotensive activities of Cryptenamine.Approved
PenbutololCryptenamine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumCryptenamine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Cryptenamine.Approved, Investigational
PerindoprilCryptenamine may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Cryptenamine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Cryptenamine.Withdrawn
PhenoxybenzamineCryptenamine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Cryptenamine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Cryptenamine.Approved
PinacidilCryptenamine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololCryptenamine may increase the hypotensive activities of Pindolol.Approved
PirlindolePirlindole may increase the hypotensive activities of Cryptenamine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Cryptenamine.Withdrawn
PolythiazideCryptenamine may increase the hypotensive activities of Polythiazide.Approved
PrazosinPrazosin may increase the hypotensive activities of Cryptenamine.Approved
PropranololPropranolol may increase the hypotensive activities of Cryptenamine.Approved, Investigational
QuinaprilCryptenamine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Cryptenamine.Approved
RamiprilRamipril may increase the hypotensive activities of Cryptenamine.Approved
RasagilineRasagiline may increase the hypotensive activities of Cryptenamine.Approved
RemikirenRemikiren may increase the hypotensive activities of Cryptenamine.Approved
RescinnamineCryptenamine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Cryptenamine.Approved
RilmenidineCryptenamine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatCryptenamine may increase the hypotensive activities of Riociguat.Approved
RituximabCryptenamine may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypotensive activities of Cryptenamine.Withdrawn
SaprisartanCryptenamine may increase the hypotensive activities of Saprisartan.Experimental
SelegilineSelegiline may increase the hypotensive activities of Cryptenamine.Approved, Investigational, Vet Approved
SelexipagCryptenamine may increase the hypotensive activities of Selexipag.Approved
SildenafilSildenafil may increase the antihypertensive activities of Cryptenamine.Approved, Investigational
SitaxentanCryptenamine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilCryptenamine may increase the hypotensive activities of Spirapril.Approved
TadalafilTadalafil may increase the antihypertensive activities of Cryptenamine.Approved, Investigational
TelmisartanCryptenamine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilCryptenamine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerlipressinCryptenamine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TiboloneCryptenamine may increase the hypotensive activities of Tibolone.Approved
TicrynafenCryptenamine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Cryptenamine.Approved
TolazolineCryptenamine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Cryptenamine.Approved
TorasemideTorasemide may increase the hypotensive activities of Cryptenamine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Cryptenamine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cryptenamine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Cryptenamine.Approved
TravoprostTravoprost may increase the hypotensive activities of Cryptenamine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Cryptenamine.Approved, Investigational
TrichlormethiazideCryptenamine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinCryptenamine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanCryptenamine may increase the hypotensive activities of Trimethaphan.Approved
UdenafilUdenafil may increase the antihypertensive activities of Cryptenamine.Approved, Investigational
UnoprostoneCryptenamine may increase the hypotensive activities of Unoprostone.Approved
ValsartanValsartan may increase the hypotensive activities of Cryptenamine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Cryptenamine.Approved
VinpocetineCryptenamine may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineCryptenamine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Cryptenamine.Approved, Vet Approved
Food InteractionsNot Available
References
Synthesis Reference

Cavallito ,C.J.; US. Patent 2,789,977; April 23,1957; assigned to Innrin, Neisler and Company.

General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
Manufacturers
  • Medpointe pharmaceuticals medpointe healthcare inc
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Jandhyala ML, Buckley JP: Mechanisms of action of cryptenamine. J Pharm Sci. 1968 Sep;57(9):1576-82. [PubMed:5674398 ]
  4. Jandhyala BS, Buckley JP: Pharmacology and mechanism of action of cryptenamine. J Pharm Sci. 1966 Sep;55(9):888-93. [PubMed:5918523 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23